Dr. Yan Peng completed her Pediatric Residency/Chief Resident at Beijing Medical University Hospitals and practiced there as a Pediatric Nephrologist for two years. After a combined six years of basic research on kidney disease at Mayo Clinic in Rochester and UT-Southwestern Medical Center (UTSW), she went to University of Pittsburgh Medical Center (UPMC) for Pathology Residency. Upon the completion, she took two fellowship trainings in Breast and Gynecologic Pathology and Cytopathology at UPMC and Harvard Medical School, respectively.
She has been a Breast and Gynecologic Surgical Pathologist and Cytopathologist at the UTSW. She is the Pathology Liaison at Cancer Committee of UTSW Simmons Cancer Center and University Hospitals. She served as Medical Directors of Diagnostic Immunohistochemistry Laboratory and Tumor Biomarker Image Analysis Laboratory for about 10 years. As co-investigator, she has participated in more than 30 National Cancer Institute (NCI) Breast and Gynecologic cancer clinical trials. She has served as an investigator for NCI Cancer Therapy Evaluation Program since 2014.
Dr. Peng authored more than 90 peer-reviewed articles and book chapters. She serves as an Editor for a textbook entitled Practical Breast Pathology (Springer). She has served as an editorial board member for multiple scientific journals including Human Pathology.
- Medical School
- Beijing Medical University (1986)
- Beijing University Hospital (1989), Pediatrics
- Graduate School
- Beijing Medical University, China (1991)
- Mayo Clinic College of Medicine (1995), Physiology
- UT Southwestern Medical Center (1999), Molecular Nephrology Research
- University of Pittsburgh Medical Center (2003), Anatomic & Clinical Pathology
- University of Pittsburgh Medical Center Magee Womens Hospital (2004), Breast & Gynecologic Pathology
- Harvard Medical School/Beth Israel Deaconess Medical Center (2005), Cytopathology
- Breast Cancer and Gynecologic Cancer Pathology
- Diagnostic Immunohistochemistry: Theranostic and Genomic Applications
- Prognostic and predictive tumor biomarkers
- CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
- Denard B, Jiang S, Peng Y, Ye J BMC Cancer 2018 Aug 18 1 813
- Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
- Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA Mol. Cancer Res. 2018 Jul
- Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
- O'Conor CJ, Chen T, González I, Cao D, Peng Y Biomark Med 2018 Jun
- ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
- Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W J. Clin. Invest. 2018 May 128 5 1937-1955
- Prognostic Role of Tumoral PDL1 Expression and Peritumoral FoxP3+ Lymphocytes in Vulvar Melanomas.
- Chlopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP Hum. Pathol. 2018 Jan
- Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
- Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D Am. J. Surg. Pathol. 2017 Sep
- Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.
- Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J Oncotarget 2017 Aug 8 33 54364-54377
- KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
- Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Marti GT, Paral K, Shalin S, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP Br. J. Dermatol. 2017 Jul
- Update on Immunohistochemical Analysis in Breast Lesions.
- Peng Y, Butt YM, Chen B, Zhang X, Tang P Arch. Pathol. Lab. Med. 2017 Jun
- Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
- Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast Cancer Res. Treat. 2015 Mar
Invasive Breast Carcinomas. In Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.).
Peng Y, Kong C, and Chen Y. (2013; 147-212). Philadelphia, PA, Elsevier
Practical Breast Pathology
Peng Y, Tang P (Ed.) (2019). New York, Springer
Immunohistochemistry in Breast Cancer. In Practical Breast Pathology
Ping Tang, Marilyn M. Bui, Yan Peng (2019). New York, Springer
Breast Cancer with Hereditary Cancer Predisposition Syndromes. In Practical Breast Pathology
Roshni Rao, Caitlin B. Mauer, Margaret Chen-Seetoo, Yan Peng (2019). New York, Springer
Honors & Awards
- Chair, Pathology Faculty Mentoring Committee
- Member, Abstract Review Board of United States and Canadian Academy of Pathology (Breast Pathology Category)
- Member, UT Southwestern Medical School Deans Standing Committee (Faculty Council)
- President, International Association of Chinese Pathologists (IACP)
- President, North Texas Society of Pathologists (NTSP)
- President, UT Southwestern Faculty Senate
- Distinguished Young Investigator Award in Medicine
Beijing, China (1993)
- Distinguished Scientist Award of Canada China Child Health Foundation
- Best National Medical Article Award
- Member, Faculty Promotion and Tenure Committee for UT Southwestern Medical School